StockNews.AI
PTGX
StockNews.AI
179 days

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

1. PTGX reports $165M icotrokinra milestone and strong cash runway. Clinical milestones and trial readouts loom. 2. Upcoming Phase 3 and 2b trial results could drive near-term stock enthusiasm.

Earnings
+0.68%Current Return
VS
-1.71%S&P 500
$38.4902/21 07:09 AM EDTEvent Start
$38.7502/24 07:25 AM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The announcement of a significant milestone, robust cash position, and imminent clinical readouts enhances investor confidence. Similar biotech pipeline updates have historically driven positive short-term price reactions.

How important is it?

Major near-term clinical events combined with a robust financial base make this update highly influential for PTGX's stock performance.

Why Short Term?

Immediate catalysts from clinical trial results expected in Q1 can quickly impact valuation, as seen in comparable biotech firms.

Related Companies

$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025 PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024 Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025 Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in March 2025 Cash, cash equivalents, and marketable securities of $559.2 million as of December 31, 2024, combined with $165.0 million milestone payment, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "Protagonist is quickly approaching multiple late-stage transformational events expected in the first quarter of this year, including the topline results from the VERIFY Phase 3 study of rusfertide in polycythemia vera and from the ANTHEM Phase 2b ulcerative colitis study of icotrokinra," said Dinesh V.

Related News